Pyrotinib is an irreversible oral pan-ErbB TKI targeting EGFR/HER1, HER2, and HER4. In a phase II study, pyrotinib monotherapy as a second- or above-line treatment in HER2-mutant NSCLC patients showed an acceptable safety profile and promising antitumor activity, with an ORR of 30% [22]. Here, ERBB2 is linked to non-small cell lung carcinoma.